Although the overexpression of hormone receptors (progesterone and estrogen) is a common characteristic of these subtypes, they frequently show lower levels of tumor-associated antigens, such HER2, which are more frequently targeted in treatments for other subtypes of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.